Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

517

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolaemia

Interventions

DRUG: Alirocumab
DRUG: Placebo
DRUG: Lipid-Modifying Therapy (LMT)
DRUG: Antihyperglycemic Drug

Sponsor

Sanofi

Collaborators

[object Object]